Literature DB >> 31065944

PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Alejandro Lloret1,2, M Flint Beal3.   

Abstract

In this review, we summarize the available published information on the neuroprotective effects of increasing nicotinamide adenine dinucleotide (NAD+) levels in Huntington's disease models. We discuss the rationale of potential therapeutic benefit of administering nicotinamide riboside (NR), a safe and effective NAD+ precursor. We discuss the agonistic effect on the Sirtuin1-PGC-1α-PPAR pathway as well as Sirtuin 3, which converge in improving mitochondrial function, decreasing ROS production and ameliorating bioenergetics deficits. Also, we discuss the potential synergistic effect of increasing NAD+ combined with PARPs inhibitors, as a clinical therapeutic option not only in HD, but other neurodegenerative conditions.

Entities:  

Keywords:  Huntington’s disease; NAD+; Nicotinamide Riboside; PARPs; PGC-1 alpha; Sirtruins

Mesh：

Substances：

Year:  2019        PMID： 31065944     DOI： 10.1007/s11064-019-02809-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN： 0364-3190            Impact factor:   3.996


  165 in total

1.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

Review 2.  Metabolic control through the PGC-1 family of transcription coactivators.

Authors:  Jiandie Lin; Christoph Handschin; Bruce M Spiegelman
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

Review 3.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  NAD+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency.

Authors:  Yujun Hou; Sofie Lautrup; Stephanie Cordonnier; Yue Wang; Deborah L Croteau; Eduardo Zavala; Yongqing Zhang; Kanako Moritoh; Jennifer F O'Connell; Beverly A Baptiste; Tinna V Stevnsner; Mark P Mattson; Vilhelm A Bohr
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-05       Impact factor: 11.205

5.  Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes.

Authors:  Ella Dragileva; Audrey Hendricks; Allison Teed; Tammy Gillis; Edith T Lopez; Errol C Friedberg; Raju Kucherlapati; Winfried Edelmann; Kathryn L Lunetta; Marcy E MacDonald; Vanessa C Wheeler
Journal:  Neurobiol Dis       Date:  2008-09-30       Impact factor: 5.996

6.  Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset.

Authors:  Meera Swami; Audrey E Hendricks; Tammy Gillis; Tiffany Massood; Jayalakshmi Mysore; Richard H Myers; Vanessa C Wheeler
Journal:  Hum Mol Genet       Date:  2009-05-23       Impact factor: 6.150

7.  An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Authors:  Sigurd D Süssmuth; Salman Haider; G Bernhard Landwehrmeyer; Ruth Farmer; Chris Frost; Giovanna Tripepi; Claus A Andersen; Marco Di Bacco; Claudia Lamanna; Enrica Diodato; Luisa Massai; Daniela Diamanti; Elisa Mori; Letizia Magnoni; Jens Dreyhaupt; Karin Schiefele; David Craufurd; Carsten Saft; Monika Rudzinska; Danuta Ryglewicz; Michael Orth; Sebastian Brzozy; Anna Baran; Giuseppe Pollio; Ralph Andre; Sarah J Tabrizi; Borje Darpo; Goran Westerberg
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

8.  OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.

Authors:  Thomas E Akie; Lijun Liu; Minwoo Nam; Shi Lei; Marcus P Cooper
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

9.  Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients.

Authors:  Georgina Askeland; Zaneta Dosoudilova; Marie Rodinova; Jiri Klempir; Irena Liskova; Anna Kuśnierczyk; Magnar Bjørås; Gaute Nesse; Arne Klungland; Hana Hansikova; Lars Eide
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

10.  Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Lior Weissman; Dong-Gyu Jo; Martin M Sørensen; Nadja C de Souza-Pinto; William R Markesbery; Mark P Mattson; Vilhelm A Bohr
Journal:  Nucleic Acids Res       Date:  2007-08-17       Impact factor: 16.971
View more
  11 in total

1.  NAD metabolism in aging and cancer.

Authors:  John Wr Kincaid; Nathan A Berger
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-05

Review 2.  NAD+ in Brain Aging and Neurodegenerative Disorders.

Authors:  Sofie Lautrup; David A Sinclair; Mark P Mattson; Evandro F Fang
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

Review 3.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

4.  The NAD+-mitophagy axis in healthy longevity and in artificial intelligence-based clinical applications.

Authors:  Yahyah Aman; Johannes Frank; Sofie Hindkjær Lautrup; Adrian Matysek; Zhangming Niu; Guang Yang; Liu Shi; Linda H Bergersen; Jon Storm-Mathisen; Lene J Rasmussen; Vilhelm A Bohr; Hilde Nilsen; Evandro F Fang
Journal:  Mech Ageing Dev       Date:  2019-12-05       Impact factor: 5.432

Review 5.  Role of PGC-1α in the Mitochondrial NAD+ Pool in Metabolic Diseases.

Authors:  Jin-Ho Koh; Jong-Yeon Kim
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 6.  The 4 D's of Pellagra and Progress.

Authors:  Adrian C Williams; Lisa J Hill
Journal:  Int J Tryptophan Res       Date:  2020-04-16

Review 7.  DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses.

Authors:  Tamara Maiuri; Claudia L K Hung; Celeste Suart; Nola Begeja; Carlos Barba-Bazan; Yi Peng; Natasha Savic; Timothy Wong; Ray Truant
Journal:  J Huntingtons Dis       Date:  2021

Review 8.  NAD+ Metabolism and Diseases with Motor Dysfunction.

Authors:  Samuel Lundt; Shinghua Ding
Journal:  Genes (Basel)       Date:  2021-11-09       Impact factor: 4.096

9.  Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study.

Authors:  Andrew McGarry; John Gaughan; Cory Hackmyer; Jacqueline Lovett; Mohammed Khadeer; Hamza Shaikh; Basant Pradhan; Thomas N Ferraro; Irving W Wainer; Ruin Moaddel
Journal:  Sci Rep       Date:  2020-11-24       Impact factor: 4.996

Review 10.  Recent Neurotherapeutic Strategies to Promote Healthy Brain Aging: Are we there yet?

Authors:  Chul-Kyu Kim; Perminder S Sachdev; Nady Braidy
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.